A cost-effectiveness analysis of an in-hospital clinical pharmacist service

BMJ Open

Volumn 2, Issue 1, 2012, Pages

  Wallerstedt, Susanna M ^a   Bladh, Lina ^a   Ramsberg, Joakim ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Swedish National Agency for Health and Care Services Analysis   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CLINICAL PHARMACY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; FEMALE; HOSPITAL COST; HOSPITAL PHARMACY; HOSPITAL SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACIST; QUALITY ADJUSTED LIFE YEAR; SWEDEN; UNIVERSITY HOSPITAL; WARD;

EID: 84859042791     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000329     Document Type: Article

References (24)

1. Leendertse AJ, Visser D, Egberts AC, et al. The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis. Drug Saf 2010;33:233-44.
2. Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoringecost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf 1997;6(Suppl 3):S71-7. (Pubitemid 27483543)
3. Rottenkolber D, Schmiedl S, Rottenkolber M, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf 2011;20:626-34.
4. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring-cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997;6(Suppl 3):S79-90. (Pubitemid 27483544)
5. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007; (4): CD000409.
6. Glintborg B, Andersen SE, Dalhoff K. Insufficient communication about medication use at the interface between hospital and primary care. Qual Saf Health Care 2007;16:34-9. (Pubitemid 46347948)
7. Midlov P, Bergkvist A, Bondesson A, et al. Medication errors when transferring elderly patients between primary health care and hospital care. Pharm World Sci 2005;27:116-20. (Pubitemid 40755038)
8. Midlov P, Holmdahl L, Eriksson T, et al. Medication report reduces number of medication errors when elderly patients are discharged from hospital. Pharm World Sci 2008;30:92-8. (Pubitemid 350172655)
9. Kaboli PJ, Hoth AB, McClimon BJ, et al. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med 2006;166:955-64.
10. Pickard AS, Hung SY. An update on evidence of clinical pharmacy services' impact on health-related quality of life. Ann Pharmacother 2006;40:1623-34. (Pubitemid 44330207)
11. Gillespie U, Alassaad A, Henrohn D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med 2009;169:894-900.
12. Holland R, Desborough J, Goodyer L, et al. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol 2008;65:303-16. (Pubitemid 351316922)
13. Bladh L, Ottosson E, Karlsson J, et al. Effects of a clinical pharmacist service on health-related quality of life and prescribing of drugs: a randomised controlled trial. BMJ Qual Saf 2011;20:738-46.
14. De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm 2008;65:1161-72. (Pubitemid 351874860)
15. Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000;17:13-35. (Pubitemid 30072853)
16. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 1999;3:1-152.
17. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96. (Pubitemid 40723857)
18. Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008;26:781-98.
19. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
20. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200. (Pubitemid 30224273)
21. Nkansah N, Mostovetsky O, Yu C, et al. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev 2010; (7): CD000336.
22. Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 2011;342:d1548.
23. Berk ML, Monheit AC. The concentration of health care expenditures, revisited. Health Aff (Millwood) 2001;20:9-18. (Pubitemid 33710272)
24. Pacini M, Smith RD, Wilson EC, et al. Home-based medication review in older people: is it cost effective? Pharmacoeconomics 2007;25:171-80. (Pubitemid 46175552)